Table 1 Baseline demographics and clinical characteristics of hallucinations group
Randomization groups | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Risperidone (N = 37) | Olanzapine (N = 37) | Quetiapine (N = 38) | Ziprasidone (N = 42) | All patients (N = 154) | ||||||
N | % | N | % | N | % | N | % | N | % | ||
Gender | |||||||||||
Male | 28 | 75.7 | 24 | 64.9 | 24 | 63.2 | 25 | 59.5 | 101 | 65.6 | |
Antipsychotic naïve | 13 | 36.1 | 14 | 37.8 | 21 | 55.3 | 22 | 52.4 | 70 | 45.8 | |
Alcohol last 6 months | |||||||||||
None | 11 | 29.7 | 6 | 16.2 | 5 | 13.2 | 8 | 19.5 | 30 | 19.6 | |
Misuse | 3 | 8.1 | 4 | 10.8 | 9 | 23.7 | 4 | 9.8 | 20 | 13.1 | |
Drugs last 6 months | |||||||||||
None | 19 | 52.8 | 26 | 70.3 | 28 | 73.7 | 26 | 63.4 | 99 | 65.1 | |
Misuse | 11 | 30.6 | 6 | 16.2 | 5 | 13.1 | 9 | 21.9 | 31 | 20.4 | |
Diagnosis 1 | |||||||||||
Schz and rel. | 18 | 52.9 | 16 | 44.5 | 24 | 63.1 | 20 | 51.3 | 78 | 53.1 | |
Acute | 2 | 5.9 | 8 | 22.2 | 3 | 7.9 | 4 | 10.3 | 17 | 11.6 | |
Drug-induced | 8 | 23.5 | 4 | 11.1 | 6 | 15.8 | 5 | 12.8 | 23 | 15.6 | |
Affective | 3 | 8.8 | 4 | 11.1 | 3 | 7.9 | 3 | 7.7 | 13 | 8.8 | |
Rest | 3 | 8.7 | 4 | 11.1 | 2 | 5.2 | 7 | 18.0 | 16 | 11.0 | |
Mean | SD | Mean | SD/Range | Mean | SD/Range | Mean | SD/Range | Mean | SD | ||
Age | 32.9 | 12.0 | 30.1 | 11.9 | 35.8 | 12.8 | 29.1 | 11.5 | 31.9 | 12.2 | |
PANSS Total | 76.8 | 13.5 | 77.2 | 14.2 | 76.2 | 14.6 | 74.4 | 12.8 | 76.1 | 13.7 | |
PANSS Positive | 20.2 | 4.6 | 21.7 | 4.6 | 21.0 | 4.2 | 20.4 | 4.6 | 20.8 | 4.5 | |
PANSS Negative | 21.7 | 8.0 | 18.7 | 7.9 | 19.8 | 7.2 | 19.0 | 7.0 | 19.8 | 7.5 | |
PANSS General | 34.8 | 6.5 | 36.9 | 7.8 | 35.3 | 7.3 | 35.0 | 6.7 | 35.5 | 7.1 | |
CDSS | 7.2 | 5.8 | 7.0 | 4.5 | 7.1 | 4.6 | 7.6 | 6.0 | 7.2 | 5.2 | |
GAF-F | 31.4 | 5.3 | 29.3 | 5.6 | 30.6 | 7.3 | 29.9 | 6.7 | 30.3 | 6.3 | |
CGI | 5.3 | 0.6 | 5.3 | 0.7 | 5.3 | 0.6 | 5.1 | 0.5 | 5.3 | 0.6 | |